Cardiovascular Effects of Glucagon-Like Peptide 1

By  

Mini Reviews in Medicinal Chemistry, Vol. 11, Iss. 1, 2011-01 ,pp. : 97-105

Bentham Science Publishers

Access to resources Recommend Favorite

Glucagon and Glucagon-Like Peptide Receptors as Drug Targets

By  

Current Pharmaceutical Design, Vol. 12, Iss. 14, 2006-05 ,pp. : 1731-1750

Bentham Science Publishers

Access to resources Recommend Favorite

Effects of Glucagon-Like Peptide-1 and Long-Acting Analogues on Cardiovascular and Metabolic Function

By Saraceni Christine   Broderick Tom L.  

Drugs in R&D, Vol. 8, Iss. 3, 2007-01 ,pp. : 145-153

Adis International

Access to resources Recommend Favorite

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

By Ribel U.   Larsen M.O.   Rolin B.   Carr R.D.   Wilken M.   Sturis J.   Westergaard L.   Deacon C.F.   Knudsen L.B.  

European Journal of Pharmacology, Vol. 451, Iss. 2, 2002-09 ,pp. : 217-225

Elsevier

Access to resources Recommend Favorite

Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes

By  

Current Pharmaceutical Design, Vol. 17, Iss. 38, 2011-01 ,pp. : 4379-4385

Bentham Science Publishers

Access to resources Recommend Favorite